Technology
Health
Pharmaceutical

Regulus Therapeutics

$1.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (3.78%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!

About

Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Employees
24
Headquarters
San Diego, California
Founded
2007
Market Cap
14.82M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
260.50K
High Today
$1.40
Low Today
$1.32
Open Price
$1.32
Volume
102.59K
52 Week High
$9.48
52 Week Low
$0.80

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
Biopharmaceutical
US
North America

News

Seeking AlphaMay 9

Regulus Therapeutics reports Q1 results

Regulus Therapeutics (NASDAQ:RGLS): Q1 GAAP EPS of -$0.31. Alliance revenue of $6.78M. Cash and cash equivalents of $10.3M; also in May 2019, closed first tranche of its $41.8M private placement and received net proceeds of ~$15.7M Press Release...

182
Yahoo FinanceMay 9

Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Engagement with FDA on RGLS4326 Clinical Program Ongoing LA JOLLA, Calif., May 9, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarte...

66
PR NewswireMay 7

Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity

133

Earnings

-$1.25
-$0.88
-$0.50
-$0.13
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.